DSpace@İnönü

Oral erdosteine administration attenuates cisplatin-induced renal

Basit öğe kaydını göster

dc.contributor.author Yildirim, Z
dc.contributor.author Sogut, S
dc.contributor.author Odaci, E
dc.contributor.author Iraz, M
dc.contributor.author Ozyurt, H
dc.contributor.author Kotuk, M
dc.contributor.author Akyol, O
dc.date.accessioned 2022-03-14T12:52:56Z
dc.date.available 2022-03-14T12:52:56Z
dc.date.issued 2003
dc.identifier.uri http://hdl.handle.net/11616/55413
dc.description.abstract The effect of oral erdosteine on tissue malondialdehyde (MDA) and nitric oxide (NO) levels, and catalase (CAT), glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities are investigated in the cisplatin model of acute renal failure in rats. A single dose of cisplatin caused kidney damage manifested by kidney histology as well as increases in plasma creatinine and blood urea nitrogen (BUN) levels. Treatment with free radical scavenger erdosteine attenuated increases in plasma creatinine and BUN, and tissue MDA and NO levels, and provided a histologically-proven protection against cisplatin-induced acute renal failure. Erdosteine also reduced depletion in the tissue CAT, GSH-Px, and SOD activities. These results show that erdosteine may be a promising drug for protection against cisplatin-induced nephrotoxicity. However, further studies with different doses of erdosteine are warranted for clarifying the issue. (C) 2002 Published by Elsevier Science Ltd.
dc.source PHARMACOLOGICAL RESEARCH
dc.title Oral erdosteine administration attenuates cisplatin-induced renal
dc.title tubular damage in rats


Bu öğenin dosyaları:

Dosyalar Boyut Biçim Göster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster